WuXi Biologics to Build $1.4B CRDMO Hub in Singapore, Creating 1,500 Jobs
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...
Fineline Cube
Antengene and Celularity Partner on Bispecific Antibody and NK Cell Therapy Combo
China-based Antengene Corporation Ltd (HKG: 6996) announced a preclinical partnership with U.S. firm Celularity Inc....
Kexing Pharmaceutical Launches Phase III Influenza Vaccine Study in Chile
China-based Kexing Pharmaceutical (SHA: 688136) announced the start of a Phase III clinical trial in...
Henlius Biotech’s HLX14 Biosimilar Wins TGA Approval for Global Phase III Osteoporosis Study
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) received approval from Australia’s Therapeutic Goods Administration (TGA)...
Luye Pharma’s Rotigotine Microspheres Meet Phase III Goals in Parkinson’s Study
China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for rotigotine...
Eli Lilly’s Retevmo Wins Special Approval in China’s Lecheng Medical Pilot Zone
Eli Lilly & Co. (NYSE: LLY) has secured special approval for its RET kinase inhibitor...
Attec Completes Pre-Series A Financing with Sequoia China Backing Protein Degradation Tech
China-based biotech startup Attec has completed a pre-Series A financing round, with its protein degradation...
Innovent Biologics’ Mazdutide Meets Phase II Goals in Type 2 Diabetes Study
China-based Innovent Biologics Inc. (HKG: 1801) announced that its Phase II study of mazdutide (IBI362/OXM3)...
Digital Precision Medicine Raises Hundreds of Millions in Series B Financing for Molecular Imaging Innovation
China-based Digital Precision Medicine (DPM), a molecular imaging and fluorescence endoscopy manufacturer, has reportedly raised...
Sihuan Pharma’s Fourth-Gen Insulin Degludec NDA Accepted by NMPA for Review
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its New Drug Application (NDA)...
Sihuan Pharma’s Anaprazole Enters Phase II Study for Reflux Esophagitis
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its subsidiary Xuanzhu Biopharmaceutical Co.,...
Takeda Opens R&D Asia-Pacific Headquarters in Shanghai to Boost Drug Development
Japan’s Takeda Pharmaceutical Co., Ltd has inaugurated its R&D Asia-Pacific headquarters in Pudong, Shanghai. The...
Tongling Bionic Raises Hundreds of Millions in Series B Financing for Cardiopulmonary Equipment Development
Anhui Tongling Bionic Technology Co., Ltd, a Chinese developer of cardiopulmonary circulatory assist equipment, has...
Sesen Bio Terminates Vicineum Development After FDA Talks, Citing Phase III Costs
Sesen Bio Inc. (NASDAQ: SESN) announced the termination of clinical development for Vicineum (VB4-845), its...
Huadong Medicine’s GFR Monitoring System Accepted by NMPA for Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a glomerular...
Roche’s Chugai Launches Edirol in China for Postmenopausal Osteoporosis
Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an...
Humanwell Healthcare’s RFUS-144 Wins NMPA Approval for Pruritus Clinical Study
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Category 1 drug RFUS-144...
Brii Biosciences Partners with Huarun Medicine to Commercialize COVID-19 Antibody Cocktail in China
China-based Brii Biosciences Ltd (HKG: 2137) announced a partnership with Huarun Medicine Business Group International...
Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China
Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China’s homegrown innovative androgen receptor (AR)...
Chongqing Lummy Pharma Cancels YZY Biopharma Y400 Partnership, Secures Compensation
China’s Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) announced the termination of its strategic partnership...